A Surprising Alzheimer’s Case Raises New Questions About Psilocybin and the Hidden Capacity of the Brain

Advanced Alzheimer’s disease is usually spoken about in terms of loss.

Loss of memory. Loss of language. Loss of independence. Loss of the person’s familiar personality, expressions, and ways of connecting. For families and caregivers, the disease can feel like a long goodbye, especially when someone they love can no longer speak much, move freely, recognize context, or participate in daily life.

That is why a recent case report published in Frontiers in Neuroscience is so striking.

The report describes an elderly Japanese-American woman with advanced Alzheimer’s disease who showed temporary improvements in speech, mobility, emotional expression, continence, and social engagement after receiving psilocybin-containing mushrooms in a supervised setting.

This was not a clinical trial. It was not proof of a cure. And it should not be interpreted as a recommendation for families to try this on their own.

But the case is still worth paying attention to, because it raises a deeply important question: in advanced dementia, are some abilities truly gone, or are some of them still present but difficult to access?

A Woman Who Had Been Declining for Years

The patient in the case report was in her eighties and had been living with Alzheimer’s disease for about 10 years. Over the previous five years, her decline had become severe.

Her speech had become mostly monosyllabic. She rarely initiated conversation. She had chronic urinary incontinence, difficulty walking without help, trouble swallowing, flat affect, and very limited emotional responsiveness. She needed continuous family supervision and caregiver support.

In other words, this was not early Alzheimer’s. This was advanced disease, the stage where families are often told that meaningful improvement is unlikely.

The Psilocybin Session

The patient was given a single oral dose of 5 grams of psilocybin-containing mushrooms, identified in the report as the Enigma strain.

The authors are clear that this was exploratory and observational. There is no established psilocybin dosing framework for people with advanced dementia, and the dose used in this case was high compared with many modern clinical research settings.

The acute phase was intense. The patient experienced profuse sweating, signs of autonomic activation, suspected hyperthermia, and what the authors described as a prolonged deep sleep-like state.

Then, about 19 hours after taking the mushrooms, something unexpected happened.

She woke up and began speaking autobiographically for several hours.

For someone who had spent years speaking mostly in one-word responses, this was remarkable.

What Changed Afterward

The changes did not stop with that first period of speech.

In the days that followed, the patient became more alert and socially engaged. She recognized family members. She made more eye contact. She smiled more. Her facial expressions became more animated. She showed more emotional reciprocity.

Her movement also improved. By the second day, she was reportedly walking independently. Soon after, she began dressing herself and showing more initiative.

One of the most notable changes was urinary continence. According to the report, she had been chronically incontinent for more than five years, but after the session, her diapers remained dry, including at night.

That detail matters because continence is not just a simple physical function. It involves awareness of the body, executive control, timing, inhibition, and coordinated brain-body communication. Seeing that function return, even temporarily, was one of the most striking parts of the case.

The patient also showed signs of memory and contextual awareness. She asked where someone had gone. She recognized a vehicle correctly. She seemed more present in the social world around her.

A month later, some of the improvements were still meaningful enough that a second supervised psilocybin session was conducted, this time with 3 grams of mushrooms. During that second session, she was reportedly more verbally expressive, emotionally warm, humorous, and physically agile. She described peaceful imagery of surfing with her son on an island.

At one point, she said, “It is pleasant to come here.”

For a person who had been largely quiet and withdrawn, that simple sentence carries a lot of weight.

Why This Case Is So Interesting

The most fascinating part of this report is not the idea that psilocybin “treated” Alzheimer’s. That would be too big a claim.

What is fascinating is the possibility that some abilities may still exist beneath the surface, even in advanced neurodegeneration.

Alzheimer’s damages the brain, but the brain is also a network. When networks become rigid, disconnected, or poorly coordinated, a person may lose access to functions that are not completely erased.

The authors suggest that psilocybin may have temporarily changed large-scale brain network activity in a way that allowed some residual capacities to come back online.

Psilocybin is known to affect serotonin 5-HT2A receptors and alter communication patterns across the brain. Studies have shown that it can shift default mode network activity, reduce rigid separation between brain networks, and increase more global forms of connectivity. Preclinical research also suggests that psychedelics may support plasticity-related processes, including changes in dendrites and synapses.

That does not mean psilocybin reverses Alzheimer’s pathology. It does not mean damaged tissue is restored.

But it may mean that, under certain conditions, the brain can temporarily access patterns of function that seemed unavailable.

The Sleep-Like State May Matter

Another intriguing part of the case was the long deep sleep-like period after the first dose.

The authors could not measure it with sleep studies, so we do not know exactly what was happening in the brain. But the sequence is hard to ignore: a powerful acute experience, a prolonged sleep-like state, and then a sudden return of autobiographical speech and functional improvements.

Sleep, memory, emotional processing, and neuroplasticity are closely connected. It is possible that this sleep-like state played some role in the changes that followed. It is also possible that it was simply part of the patient’s response to psilocybin.

At this point, we do not know. But future research should pay close attention to sleep, especially in people with dementia.

A Very Important Word of Caution

As moving as this case is, it has limitations.

It was one person. There was no placebo group. There were no standardized cognitive tests before and after the intervention. There was no brain imaging, no biomarker confirmation, no EEG, and no formal sleep monitoring.

The diagnosis was clinically consistent with Alzheimer’s disease, but the authors acknowledge that other factors, including vascular changes or mixed dementia, could not be completely ruled out.

It is also impossible to prove that psilocybin caused the improvements. Dementia symptoms can fluctuate. Caregiver observations can be influenced by hope, attention, and emotional context. Other unknown factors may have played a role.

The safety concerns also matter. The patient experienced sweating, suspected hyperthermia, and a prolonged altered state. In a frail elderly person, those symptoms could be dangerous. This is not something families should attempt outside of medical and research settings.

What This Case Really Shows

This case does not show that psilocybin cures Alzheimer’s disease.

It does not show that psilocybin reverses dementia.

It does not provide a protocol for treatment.

What it does show is that one woman with advanced Alzheimer’s disease experienced temporary, meaningful improvements after psilocybin administration. Those improvements touched several areas at once: language, memory, continence, movement, emotional expression, and social connection.

That is enough to justify curiosity.

For researchers, this case points toward a new set of questions about neuroplasticity, network flexibility, and what may still be possible in advanced dementia. For families, it offers a tender and complicated thought: perhaps the person they love is not as unreachable as they sometimes seem. For clinicians, it is a reminder that careful research is needed before hope becomes hype.

A Door Opens, But Carefully

The most responsible response to this case is not to rush toward conclusions. It is to study it carefully.

Future research would need medical monitoring, ethical safeguards, standardized assessments, neuroimaging, biomarkers, caregiver reports, and long-term follow-up. It would also need to ask who, if anyone, might benefit from this kind of intervention, and who might be harmed by it.

Still, this case gives us something meaningful to consider.

Maybe advanced Alzheimer’s is not always a simple story of disappearance. Maybe, in some cases, there are still traces of memory, personality, humor, recognition, and connection waiting beneath the surface.

And maybe the future of dementia care will not only ask how to slow decline, but also how to support the brain’s remaining capacity through every possible pathway.

That includes prevention.

Alzheimer’s prevention deserves far more attention, especially through the lens of metabolic health. The brain is deeply connected to blood sugar regulation, insulin sensitivity, inflammation, mitochondrial function, vascular health, sleep, movement, and nutrition. Long before symptoms appear, these systems may influence whether the brain is protected or placed under greater stress.

Diet is one of the most accessible places to begin. A low-inflammatory, nutrient-dense way of eating may help support the terrain of the brain and body. For some people, this may include a Mediterranean-style or MIND-style diet. For others, especially under medical supervision, a ketogenic or modified ketogenic diet may be worth exploring because of its potential to support brain energy metabolism and ketone availability.

This does not mean diet is a cure for Alzheimer’s disease. It is not that simple. But food can still matter deeply.

Even after symptoms appear, dietary support may make a meaningful difference in quality of life, inflammation, energy, mood, sleep, metabolic stability, and overall resilience. Families are often told there is little they can do once dementia progresses, but supportive care does not have to be passive. Nourishment, blood sugar balance, movement, connection, sleep support, and reducing inflammatory burden may all be part of a more compassionate and comprehensive approach.

This case report focused on psilocybin and the possibility of temporarily restoring access to hidden capacities in the brain. But it also points to a larger truth: the brain is not separate from the body. If we want to care for memory, identity, and consciousness, we must also care for metabolism, inflammation, nourishment, and the whole human being.

The future of Alzheimer’s care may require both bold research and everyday prevention. It may ask us to explore new frontiers like psychedelics while also returning to foundational questions: How do we feed the brain? How do we reduce inflammation? How do we protect metabolic health? And how do we support the person who is still there, even when the disease makes them harder to reach?

References

Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138–2143. https://doi.org/10.1073/pnas.1119598109

Dhana, K., Agarwal, P., James, B. D., Leurgans, S. E., Rajan, K. B., Aggarwal, N. T., et al. (2023). Trial of the MIND diet for prevention of cognitive decline in older persons. The New England Journal of Medicine, 389, 602–611. https://doi.org/10.1056/NEJMoa2302368

Lago, M., Cerveira, M., & Simonet, J. X. (2026). Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: A case report. Frontiers in Neuroscience, 20, 1813281. https://doi.org/10.3389/fnins.2026.1813281

Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, 404(10452), 572–628. https://doi.org/10.1016/S0140-6736(24)01296-0

Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., et al. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170–3182. https://doi.org/10.1016/j.celrep.2018.05.022

Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., et al. (2021). Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. European Neuropsychopharmacology, 50, 121–132. https://doi.org/10.1016/j.euroneuro.2021.06.001

Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., et al. (2024). Psilocybin desynchronizes the human brain. Nature, 632, 131–138. https://doi.org/10.1038/s41586-024-07624-5

Taylor, M. K., Sullivan, D. K., Mahnken, J. D., Burns, J. M., & Swerdlow, R. H. (2023). Ketogenic interventions in mild cognitive impairment, Alzheimer’s disease, and Parkinson’s disease: A systematic review and critical appraisal. Frontiers in Neurology, 14, 1123290. https://doi.org/10.3389/fneur.2023.1123290

Vann Jones, S. A., & O’Kelly, A. (2020). Psychedelics as a treatment for Alzheimer’s disease dementia. Frontiers in Synaptic Neuroscience, 12, 34. https://doi.org/10.3389/fnsyn.2020.00034